Biological E seeks EUA for Corbevax for children

In February, the Biological E had received the EUA for Corbevax from India's drug regulator Drugs Controller General of India (DCGI) for the 12 to 18 age group.

Corbevax is India's first indigenously developed Receptor Binding Domain (RBD) Protein sub-unit vaccine against Covid-19.

Read Also - Biological E bags DCGI nod for Corbevax trials as booster dose

The RBD is a part of the spike protein of SARS-CoV-2. The virus uses the spike protein to attach itself to host cells.

The DCGI had also approved Corbevax for restricted use in emergency situation among adults on December 28, 2021. The Biological E received the approval for restricted use in an emergency situation in adolescents aged 12 to less than 18 years based on interim results of the ongoing phase II/III clinical study.

Corbevax is India's third indigenous Covid-19 vaccine after Covaxin and Zydus Cadila's ZyCoV-D vaccine.

Read Also - Corbevax gets DCGI emergency use nod for 12-18 age group

Established during the 'Swadeshi Movement' of India, Biological E. Limited (BE) started during a time when the nation sought access to critical healthcare products. Founded and led by Dr. DVK Raju, Biological E. Limited commenced its operations in 1953 as a biological products company manufacturing liver extracts and anti-coagulants.

With an objective of transitioning from treating diseases to preventing them, Biological E. Limited launched its Biotechnology Division (now Vaccines and Biologics Division) and commenced large-scale production of DPT vaccines as early as 1962.

Biological E. Limited continues to evolve as an organisation and currently has four strategic business units: Branded Formulations, Speciality Generic Injectables, Synthetic Biology and Vaccines and Biologics.

Read Also - Biological E Corbevax safe, offers high antibody levels: NTAGI Chairman